Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

著者: Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi, Z. Reguiaï, Alice B. Gottlieb, Falk G. Bechara, C. Paul, Evangelos J. Giamarellos Bourboulis, A. Villani, Andreas Schwinn, Franziska Ruëff, Larisha Pillay Ramaya, Adam Reich, Inês Lobo, Rodney Sinclair, Thierry Passeron, Antonio Martorell, Pedro Mendes‐Bastos, Georgios Kokolakis, Pierre‐André Bécherel, Magdalena B. Wozniak, Angela Llobet Martinez, Xiaoling Wei, Lorenz Uhlmann, Anna Passera, Deborah Keefe, Ruvie Martin, Clarice Field, Li Chen, Marc Vandemeulebroecke, Shoba Ravichandran, Elisa Muscianisi - The Lancet 2023 被引用: 302